Genzyme
E561775
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Genzyme canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6006184 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Genzyme Context triple: [Sanofi, subsidiary, Genzyme]
-
A.
Alexion Pharmaceuticals
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
D.
Novartis
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
-
E.
Novo Nordisk
Novo Nordisk is a global healthcare company based in Denmark, best known as a leading producer of insulin and other diabetes care treatments.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Genzyme Target entity description: Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
-
A.
Alexion Pharmaceuticals
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company known for developing and manufacturing innovative medicines in areas such as oncology, immunology, and cardiovascular disease.
-
D.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
E.
Novartis
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf | biotechnology company ⓘ |
| acquiredBy | Sanofi NERFINISHED ⓘ |
| acquisitionDate | 2011 ⓘ |
| acquisitionValue | 20100000000 USD ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| developsTreatmentFor |
Fabry disease
ⓘ
Gaucher disease NERFINISHED ⓘ Pompe disease NERFINISHED ⓘ chronic kidney disease ⓘ multiple sclerosis ⓘ |
| dissolvedAsIndependentCompany | 2011 ⓘ |
| focusesOn |
endocrinology
ⓘ
genetic disorders ⓘ lysosomal storage disorders ⓘ multiple sclerosis ⓘ oncology ⓘ rare diseases ⓘ renal disease ⓘ |
| formerName | Genzyme Corporation NERFINISHED ⓘ |
| foundedBy |
Alex Grass
NERFINISHED
ⓘ
George M. Whitesides NERFINISHED ⓘ Henry Blair NERFINISHED ⓘ James Cavanaugh NERFINISHED ⓘ Sheridan Snyder NERFINISHED ⓘ |
| hasProduct |
Aubagio
NERFINISHED
ⓘ
Cerezyme NERFINISHED ⓘ Fabrazyme NERFINISHED ⓘ Lemtrada NERFINISHED ⓘ Lumizyme NERFINISHED ⓘ Myozyme NERFINISHED ⓘ Renagel NERFINISHED ⓘ Renvela NERFINISHED ⓘ Thymoglobulin NERFINISHED ⓘ |
| headquartersLocation | Cambridge, Massachusetts NERFINISHED ⓘ |
| inception | 1981 ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| locatedIn | Massachusetts ⓘ |
| numberOfEmployees | approximately 10000 ⓘ |
| operatesIn |
Asia
ⓘ
Europe ⓘ North America ⓘ |
| parentOrganization | Sanofi NERFINISHED ⓘ |
| specializesIn |
enzyme replacement therapy
ⓘ
orphan drugs ⓘ |
| stockExchangeListing | formerly NASDAQ:GENZ ⓘ |
| subsidiaryOf | Sanofi NERFINISHED ⓘ |
| website | https://www.sanofigenzyme.com ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Genzyme Description of subject: Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.